Pharma News Briefs

• According to SCOTUSblog, Pfizer filed an emergency plea with the Supreme Court yesterday, asking the Court to delay the effect of the Federal Circuit's rulings against Pfizer in the Norvasc case.  Separately, Pfizer filed a petition for certiorari and a motion for expedited review of the Federal Circuit's March 22 decision invalidating three claims of Pfizer's patent on Norvasc.
• Novartis announced Tuesday that the U.S. district court judge overseeing the Lotrel case has extended a temporary restraining order, preventing Teva from shipping any additional generic Lotrel tablets until he rules on Novartis's motion for a preliminary injunction.  Teva reportedly shipped a 3-month supply of generic Lotrel before the TRO issued.  The judge has not ordered Teva to recall the already-shipped Lotrel from the market.
• FDA Law Blog has two interesting recent posts, one on a new follow-on biologics report and the other on new FDA draft guidance entitled "Bioequivalence Recommendations for Specific Products."
• Reuters reported last week that Apotex has launched its generic Norvasc.